Ed is currently a member of the US Tarceva marketing team at Genentech, Roche Group, where he is launching a new indication for the drug in lung cancer. Previously, he was an Associate Director of Pipeline and Portfolio Planning, where he led business strategy and decision analyses across many R&D teams, therapeutic areas and corporate initiatives. Prior to Genentech, he was a Portfolio Manager and Health Care Sector Head at Calypso Capital Management, and Senior Research Analyst at Origin Capital Management.

Ed began his career in equity research at Citigroup’s top-ranked biotechnology team (including 2001 Institutional Investor #1 and 2002 Greenwich #1 ranking) and moved with the same team to Credit Suisse and UBS, where he was an Associate Director. Ed received his MD from Northwestern University and his BA from Yale with Distinction in English Language and Literature.